Inventor · disambiguated record
Owen O'Connor
Also filed as: O'CONNOR OWEN · O'CONNOR OWEN A · O'CONNOR OWEN ANTHONY · OCONNOR OWEN
13 granted patents·13 pending applications·33 citations·filing 2005–2024
88Inventor score
Files withUNIV COLUMBIA11SIGILON THERAPEUTICS INC5SLOAN KETTERING INST CANCER4O'CONNOR OWEN A3CALIFANO ANDREA1
Top patents by PatentIndex Score
26 records- 0191US7622470B2Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterinSLOAN KETTERING INST CANCER·Filed 2005·Granted Nov 24, 2009·15 cites·161 claims
- 0288US7939530B2Treatment of lymphoma using 10-propargyl-10-deazaaminopterin and gemcitabineSLOAN KETTERING INST CANCER·Filed 2005·Granted May 10, 2011·9 cites·15 claims
- 0381US10653648B2Histone acetyltransferase activators and compositions and uses thereofUNIV COLUMBIA·Filed 2017·Granted May 19, 2020·3 cites·5 claims
- 0480US11406608B2Histone acetyltransferase activators and compositions and uses thereofUNIV COLUMBIA·Filed 2020·Granted Aug 9, 2022·1 cites·24 claims
- 0579US8299078B2Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterinO'CONNOR OWEN A·Filed 2009·Granted Oct 30, 2012·3 cites·58 claims
- 0678US12161760B2Implantable particles and related methodsSIGILON THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2024·2 cites·27 claims
- 0777US12239618B2Histone acetyltransferase activators and compositions and uses thereofUNIV COLUMBIA·Filed 2022·Granted Mar 4, 2025·0 cites·14 claims
- 0875US11191768B2Histone acetyltransferase activators and uses thereofUNIV COLUMBIA·Filed 2019·Granted Dec 7, 2021·0 cites·4 claims
- 0972US2025235409A1Implantable particles and related methodsSIGILON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1063US2023167451A1Combination therapy of lymphomaUNIV COLUMBIA·Filed 2023·Application pending·0 cites
- 1162US11597933B2Combination therapy of lymphomaUNIV COLUMBIA·Filed 2018·Granted Mar 7, 2023·0 cites·15 claims
- 1259US8168404B2Methods to treat cancer with 10-propargyl-10-deazaaminopterin and methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterinO'CONNOR OWEN A·Filed 2009·Granted May 1, 2012·0 cites·20 claims
- 1358US2009269772A1Systems and methods for identifying combinations of compounds of therapeutic interestCALIFANO ANDREA·Filed 2009·Application pending·0 cites
- 1457US2013053391A1Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterinSLOAN KETTERING INST CANCER·Filed 2012·Application pending·0 cites
- 1555US2008188479A1Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterinSLOAN KETTERING INST CANCER·Filed 2007·Application pending·0 cites
- 1654US10882863B2Compounds for reducing c-Myc in c-Myc overexpressing cancers backgroundUNIV COLUMBIA·Filed 2017·Granted Jan 5, 2021·0 cites·19 claims
- 1753US9896420B2N-quinolin-benzensulfonamides and related compounds for the treatment of cancer, autoimmune disorders and inflammationUNIV COLUMBIA·Filed 2013·Granted Feb 20, 2018·0 cites·2 claims
- 1853US2018360842A1Histone Acetyltransferase Activators and Uses ThereofUNIV COLUMBIA·Filed 2018·Application pending·0 cites
- 1947US2023123802A1Compositions, devices, and methods for factor vii therapySIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2045US2014127316A1Propolis and caffeic acid phenethyl ester and uses thereofUNIV NEW YORK·Filed 2012·Application pending·0 cites
- 2145US2017182054A1Histone acetyltransferase activators and uses thereofUNIV COLUMBIA·Filed 2015·Application pending·0 cites
- 2244US2022000789A1Implantable devices for cell therapy and related methodsSIGILON THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2343US2022267794A1Compositions, devices, and methods for treating fabry diseaseSIGILON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2441US8263354B2Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterinO'CONNOR OWEN A·Filed 2010·Granted Sep 11, 2012·0 cites·7 claims
- 2536US2019070183A1Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune DiseasesUNIV COLUMBIA·Filed 2016·Application pending·0 cites
- 2623US2018140724A1Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of CancerDENG CHANGCHUN·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →